1. Home
  2. PGEN vs DCTH Comparison

PGEN vs DCTH Comparison

Compare PGEN & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Precigen Inc.

PGEN

Precigen Inc.

HOLD

Current Price

$6.97

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

DCTH

Delcath Systems Inc.

N/A

Current Price

$16.13

Market Cap

578.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PGEN
DCTH
Founded
1998
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
578.4M
IPO Year
2013
2015

Fundamental Metrics

Financial Performance
Metric
PGEN
DCTH
Price
$6.97
$16.13
Analyst Decision
Buy
Strong Buy
Analyst Count
5
4
Target Price
$8.33
$22.00
AVG Volume (30 Days)
4.1M
367.8K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
107.53
EPS
0.03
0.04
Revenue
$230,981,000.00
N/A
Revenue This Year
$1,115.92
$24.54
Revenue Next Year
$81.04
$33.15
P/E Ratio
$228.33
$397.75
Revenue Growth
N/A
N/A
52 Week Low
$2.99
$8.12
52 Week High
$7.72
$17.42

Technical Indicators

Market Signals
Indicator
PGEN
DCTH
Relative Strength Index (RSI) 52.26 57.71
Support Level $6.60 $9.98
Resistance Level $7.30 $17.42
Average True Range (ATR) 0.27 0.39
MACD -0.09 -0.20
Stochastic Oscillator 26.38 52.60

Price Performance

Historical Comparison
PGEN
DCTH

About PGEN Precigen Inc.

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: